Beijing-Based Holox Secures Tens of Millions in Series A+ Financing for Healthcare Software
Holox, a Beijing-based developer of healthcare management software, has reportedly secured tens of millions of...
Shanghai Kingstar Winning Secures $43.39 Million in Series C Financing for Digital Healthcare Solutions
Shanghai Kingstar Winning Software Science and Technology Co., Ltd, a leading provider of digitalization risk...
Luzhu Biotech Prepares for HKD 433 Million IPO with Focus on Vaccines and Biologics
Beijing Luzhu Biotechnology Co., Ltd, a leading manufacturer of human vaccines and therapeutic biologics, is...
Gan & Lee Pharmaceuticals Receives Marketing Approval for Insulin Glargine in Bolivia
Gan & Lee Pharmaceuticals (SHA: 603087), a China-based pharmaceutical company, has announced that it has...
Rainmed Medical’s caIMR System Receives NMPA Approval for Coronary Artery Function Measurement
China-based Rainmed Medical Limited has announced that it has received market approval from the National...
WuXi AppTec Reports 5.77% YOY Revenue Growth and 31.97% Increase in Net Profits for 2023Q1
WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) has released its financial report for the...
SMPA Suspends Procurement of Levornidazole by Warrant Pharmaceutical Over IP Concerns
Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has released a notification to suspend the procurement status...
Tot Biopharmaceutical Partners with Suzhou Smart Nuclide on Radioactive Drug Development
China-based Tot Biopharmaceutical International Co., Ltd (HKG: 1875) has announced a strategic partnership with Suzhou...
GSK’s Cervarix Receives Approval for Two-Dose Schedule in China for Ages 9 to 14
The UK-based pharmaceutical giant GSK plc (NYSE: GSK) has announced the official market launch of...
Everest Medicines’ Nefecon for IgAN Approved for Clinical Use in Hainan
China-based Everest Medicines (HKG: 1952) has announced that Nefecon (delayed-release budesonide), the first-in-disease treatment for...
Grand Pharmaceutical Group to Acquire Majority Stake in BlackSwan Vascular Inc. for $37.5 Million
Grand Pharmaceutical Group Limited (HKG: 0512), a China-based pharmaceutical company, has announced plans to acquire...
Zelgen Biopharmaceuticals’ ZG2001 Receives US FDA Clinical Trial Approval for Pan-KRAS Inhibitor
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial...
Sichuan Biokin Pharmaceutical Gets NMPA Approval for Two Clinical Studies on Cancer Therapies
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced receiving approval...
YiChang HEC ChangJiang Pharmaceutical Reports 309.83% YOY Revenue Growth in 2022 Financials
YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558), a China-based pharmaceutical company, has released its...
LianBio Appoints Pascal Qian as COO in Anticipation of Mavacamten Market Launch
China-based biotech firm LianBio (OTCMKTS: LIANY) has announced the promotion of its current China General...
Suzhou Basecare Medical and Qitan Tech Partner to Advance Nanopore Sequencing in PGT
Suzhou Basecare Medical Co., Ltd (HKG: 2170), a China-based in vitro fertilization (IVF) specialist, has...
Jiangsu Hengrui Pharmaceuticals’ Pyrotinib Gains NMPA Approval for HER2+ Breast Cancer Treatment
Jiangsu Hengrui Pharmaceuticals (SHA: 600276), a leading China-based pharmaceutical company, has announced receiving another indication...
Evopoint Biosciences Gets CDE Approval for Phase I/II Study of XNW27011 ADC
Suzhou Evopoint Biosciences Co., Ltd., a China-based pharmaceutical company, has announced receiving approval from the...
China’s NHC Advances Enhanced Recovery After Surgery (ERAS) Protocols Nationwide
The National Health Commission (NHC) has released a notification with the goal of promoting enhanced...
ChengDu ShengNuo Biotech Secures NMPA Approval for Generic Firazyr Equivalent
ChengDu ShengNuo Biotech Co., Ltd (SHA: 688117), a China-based polypeptide specialist, has announced that it...